Canaccord Genuity Maintains Buy on Niagen Bioscience, Lowers Price Target to $7

Benzinga · 2d ago
Canaccord Genuity analyst Susan Anderson maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and lowers the price target from $9 to $7.